{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:17:15Z","timestamp":1774279035675,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T00:00:00Z","timestamp":1482278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T00:00:00Z","timestamp":1482278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The penetration of anticancer drugs in solid tumors is important to ensure the therapeutic effect, so methods are needed to understand drug distribution in different parts of the tumor. Mass spectrometry imaging (MSI) has great potential in this field to visualize drug distribution in organs and tumor tissues with good spatial resolution and superior specificity. We present an accurate and reproducible imaging method to investigate the variation of drug distribution in different parts of solid tumors. The method was applied to study the distribution of paclitaxel in three ovarian cancer models with different histopathological characteristics and in colon cancer (HCT116), breast cancer (MDA-MB-231) and malignant pleural mesothelioma (MPM487). The heterogeneous drug penetration in the tumors is evident from the MALDI imaging results and from the images analysis. The differences between the various models do not always relate to significant changes in drug content in tumor homogenate examined by classical HPLC analysis. The specificity of the method clarifies the heterogeneity of the drug distribution that is analyzed from a quantitative point of view too, highlighting how marked are the variations of paclitaxel amounts in different part of solid tumors.<\/jats:p>","DOI":"10.1038\/srep39284","type":"journal-article","created":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T11:44:50Z","timestamp":1482320690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging"],"prefix":"10.1038","volume":"6","author":[{"given":"Silvia","family":"Giordano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Zucchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Decio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Cesca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Fuso Nerini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marika","family":"Maiezza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariella","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simonetta Andrea","family":"Licandro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Frapolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Giavazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u2019Incalci","family":"Maurizio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Davoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lavinia","family":"Morosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,21]]},"reference":[{"key":"BFsrep39284_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1517\/17425255.2011.545053","volume":"7","author":"M Pellegatti","year":"2011","unstructured":"Pellegatti, M. & Pagliarusco, S. Drug and metabolite concentrations in tissues in relationship to tissue adverse findings: a review. Expert Opin Drug Metab Toxicol 7(2), 137 (2011).","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"BFsrep39284_CR2","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/clpt.2014.105","volume":"96","author":"I Fuso Nerini","year":"2014","unstructured":"Fuso Nerini, I. et al. Intratumor heterogeneity and its impact on drug distribution and sensitivity. Clin Pharmacol Ther 96(2), 224 (2014).","journal-title":"Clin Pharmacol Ther"},{"key":"BFsrep39284_CR3","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1021\/ac504734s","volume":"87","author":"A Nilsson","year":"2015","unstructured":"Nilsson, A. et al. Mass spectrometry imaging in drug development. Anal Chem 87(3), 1437 (2015).","journal-title":"Anal Chem"},{"key":"BFsrep39284_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrc1893","volume":"6","author":"AI Minchinton","year":"2006","unstructured":"Minchinton, A. I. & Tannock, I. F. Drug penetration in solid tumours. Nat Rev Cancer 6(8), 583 (2006).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep39284_CR5","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ctrv.2014.05.008","volume":"40","author":"G Damia","year":"2014","unstructured":"Damia, G. & Garattini, S. The pharmacological point of view of resistance to therapy in tumors. Cancer Treat Rev 40(8), 909 (2014).","journal-title":"Cancer Treat Rev"},{"key":"BFsrep39284_CR6","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.coph.2013.06.003","volume":"13","author":"L Morosi","year":"2013","unstructured":"Morosi, L., Zucchetti, M., D\u2019Incalci, M. & Davoli, E. Imaging mass spectrometry: challenges in visualization of drug distribution in solid tumors. Curr Opin Pharmacol 13(5), 807 (2013).","journal-title":"Curr Opin Pharmacol"},{"key":"BFsrep39284_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11481-009-9162-6","volume":"5","author":"Y Sugiura","year":"2010","unstructured":"Sugiura, Y. & Setou, M. Imaging mass spectrometry for visualization of drug and endogenous metabolite distribution: toward in situ pharmacometabolomes. J Neuroimmune Pharmacol 5(1), 31 (2010).","journal-title":"J Neuroimmune Pharmacol"},{"key":"BFsrep39284_CR8","doi-asserted-by":"publisher","first-page":"4999","DOI":"10.1016\/j.jprot.2012.07.028","volume":"75","author":"B Prideaux","year":"2012","unstructured":"Prideaux, B. & Stoeckli, M. Mass spectrometry imaging for drug distribution studies. J Proteomics 75(16), 4999 (2012).","journal-title":"J Proteomics"},{"key":"BFsrep39284_CR9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.clinbiochem.2013.01.018","volume":"46","author":"C Schone","year":"2013","unstructured":"Schone, C., Hofler, H. & Walch, A. MALDI imaging mass spectrometry in cancer research: combining proteomic profiling and histological evaluation. Clin Biochem 46(6), 539 (2013).","journal-title":"Clin Biochem"},{"key":"BFsrep39284_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1208\/s12248-009-9158-4","volume":"J12","author":"EG Solon","year":"2010","unstructured":"Solon, E. G., Schweitzer, A., Stoeckli, M. & Prideaux, B. Autoradiography, MALDI-MS, and SIMS-MS imaging in pharmaceutical discovery and development.AAPS J12(1), 11 (2010).","journal-title":"AAPS"},{"key":"BFsrep39284_CR11","doi-asserted-by":"publisher","first-page":"e72532","DOI":"10.1371\/journal.pone.0072532","volume":"8","author":"L Morosi","year":"2013","unstructured":"Morosi, L. et al. Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging. PLoS One 8(8), e72532 (2013).","journal-title":"PLoS One"},{"key":"BFsrep39284_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/1535-7163.MCT-15-0063","volume":"15","author":"M Cesca","year":"2016","unstructured":"Cesca, M. et al. Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response. Mol Cancer Ther 15(1), 125 (2016).","journal-title":"Mol Cancer Ther"},{"key":"BFsrep39284_CR13","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.1021\/ac201602s","volume":"83","author":"K Shrivas","year":"2011","unstructured":"Shrivas, K., Hayasaka, T., Sugiura, Y. & Setou, M. Method for simultaneous imaging of endogenous low molecular weight metabolites in mouse brain using TiO2 nanoparticles in nanoparticle-assisted laser desorption\/ionization-imaging mass spectrometry. Anal Chem 83(19), 7283 (2011).","journal-title":"Anal Chem"},{"key":"BFsrep39284_CR14","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1016\/j.jprot.2012.07.035","volume":"75","author":"G Hamm","year":"2012","unstructured":"Hamm, G. et al. Quantitative mass spectrometry imaging of propranolol and olanzapine using tissue extinction calculation as normalization factor. J Proteomics 75(16), 4952 (2012).","journal-title":"J Proteomics"},{"key":"BFsrep39284_CR15","doi-asserted-by":"publisher","first-page":"10568","DOI":"10.1021\/ac502177y","volume":"86","author":"K Huber","year":"2014","unstructured":"Huber, K. et al. Novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues. Anal Chem 86(21), 10568 (2014).","journal-title":"Anal Chem"},{"key":"BFsrep39284_CR16","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s00216-014-8237-2","volume":"407","author":"A Buck","year":"2015","unstructured":"Buck, A. et al. Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI. Anal Bioanal Chem 407(8), 2107 (2015).","journal-title":"Anal Bioanal Chem"},{"key":"BFsrep39284_CR17","doi-asserted-by":"publisher","first-page":"9467","DOI":"10.1007\/s00216-013-7393-0","volume":"405","author":"S Schulz","year":"2013","unstructured":"Schulz, S. et al. DMSO-enhanced MALDI MS imaging with normalization against a deuterated standard for relative quantification of dasatinib in serial mouse pharmacology studies. Anal Bioanal Chem 405(29), 9467 (2013).","journal-title":"Anal Bioanal Chem"},{"key":"BFsrep39284_CR18","first-page":"4941","volume":"75","author":"P Kallback","year":"2012","unstructured":"Kallback, P., Shariatgorji, M., Nilsson, A. & Andren, P. E. Novel mass spectrometry imaging software assisting labeled normalization and quantitation of drugs and neuropeptides directly in tissue sections. J Proteomics 75(16), 4941 (2012).","journal-title":"Novel mass spectrometry imaging software assisting labeled normalization and quantitation of drugs and neuropeptides directly in tissue sections. J Proteomics"},{"key":"BFsrep39284_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/mas.20104","volume":"26","author":"DS Peterson","year":"2007","unstructured":"Peterson, D. S. Matrix-free methods for laser desorption\/ionization mass spectrometry. Mass Spectrom Rev 26(1), 19 (2007).","journal-title":"Mass Spectrom Rev"},{"key":"BFsrep39284_CR20","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jasms.2009.12.014","volume":"21","author":"RF Reich","year":"2010","unstructured":"Reich, R. F., Cudzilo, K., Levisky, J. A. & Yost, R. A. Quantitative MALDI-MS(n) analysis of cocaine in the autopsied brain of a human cocaine user employing a wide isolation window and internal standards. J Am Soc Mass Spectrom 21(4), 564 (2010).","journal-title":"J Am Soc Mass Spectrom"},{"key":"BFsrep39284_CR21","doi-asserted-by":"publisher","first-page":"6980","DOI":"10.1158\/0008-5472.CAN-14-0274","volume":"74","author":"F Ricci","year":"2014","unstructured":"Ricci, F. et al. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res 74(23), 6980 (2014).","journal-title":"Cancer Res"},{"key":"BFsrep39284_CR22","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S0959-8049(97)10123-X","volume":"34","author":"M Miyazaki","year":"1998","unstructured":"Miyazaki, M. et al. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin\/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095. Eur J Cancer 34(5), 710 (1998).","journal-title":"Eur J Cancer"},{"key":"BFsrep39284_CR23","doi-asserted-by":"crossref","unstructured":"Vazquez, R. et al. Promising in vivo efficacy of the BET bromodomain inhibitor OTX015\/MK-8628 in malignant pleural mesothelioma xenografts. Int J Cancer (2016).","DOI":"10.1002\/ijc.30412"},{"key":"BFsrep39284_CR24","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ajpath.2013.12.030","volume":"184","author":"A Decio","year":"2014","unstructured":"Decio, A. et al. Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. Am J Pathol 184(4), 1050 (2014).","journal-title":"Am J Pathol"},{"key":"BFsrep39284_CR25","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jss.2007.04.021","volume":"147","author":"A Rajput","year":"2008","unstructured":"Rajput, A. et al. Characterization of HCT116 human colon cancer cells in an orthotopic model. J Surg Res 147(2), 276 (2008).","journal-title":"J Surg Res"},{"key":"BFsrep39284_CR26","first-page":"1429","volume":"7","author":"FY Lee","year":"2001","unstructured":"Lee, F. Y. et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7(5), 1429 (2001).","journal-title":"Clin Cancer Res"},{"key":"BFsrep39284_CR27","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1038\/onc.2013.207","volume":"32","author":"KM Henkels","year":"2013","unstructured":"Henkels, K. M. et al. Phospholipase D (PLD) drives cell invasion, tumor growth and metastasis in a human breast cancer xenograph model. Oncogene 32(49), 5551 (2013).","journal-title":"Oncogene"},{"key":"BFsrep39284_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/sj.bjc.6605415","volume":"102","author":"SB Donaldson","year":"2010","unstructured":"Donaldson, S. B. et al. Enhancing fraction measured using dynamic contrast-enhanced MRI predicts disease-free survival in patients with carcinoma of the cervix. Br J Cancer 102(1), 23 (2010).","journal-title":"Br J Cancer"},{"key":"BFsrep39284_CR29","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1593\/neo.09866","volume":"11","author":"M Cesca","year":"2009","unstructured":"Cesca, M. et al. The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma. Neoplasia 11(11), 1155 (2009).","journal-title":"Neoplasia"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep39284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep39284","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep39284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T02:44:41Z","timestamp":1672886681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep39284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep39284"],"URL":"https:\/\/doi.org\/10.1038\/srep39284","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,21]]},"assertion":[{"value":"25 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39284"}}